Search bioRxiv⌕ Search

Biology subjects

Park, B. Y.

Publications and source records attributed to Park, B. Y..

4 recordsLinked to original sources

AbPACER: parent-aware, affinity-label-blind prioritization of affinity-matured scFv clones from phage-display NGS

Background: Affinity-maturation phage-display next-generation sequencing (NGS) yields more paired single-chain variable fragment clones than can be characterized experimentally, creating a fixed-budget prioritization problem. Read counts provide empirical support rather than direct affinity labels. We developed AbPACER (Antibody Parent-Aware Contextual Evidence Ranker), an affinity-label-blind neural ranker combining parent-relative mutation descriptors, frozen antibody-language-model context, and NGS evidence from related clones. AbPACER is campaign-adaptive rather than zero-shot: for each campaign, it is fitted to paired sequences and round-resolved R1-R3 counts before returning a 384-candidate assay list. We evaluated it in two retrospective phage-display campaigns and separately assessed its supervised mean-squared-error adaptation on AlphaSeq, denoted AbPACER-MSE. Results: From frozen top-5% candidate sets containing 16,323 Fas-associated factor 1 (FAF1) and 7,487 vascular endothelial growth factor receptor (VEGFR) clones, each method ranked the complete target-specific set and selected 384 candidates. In FAF1, AbPACER recovered 2.00 +/- 0.00 of seven retrospective panel clones, recovering two in every seed, compared with 1/7 by total count, 1.00 +/- 0.00 by Ens-Grad CNN, 1.67 +/- 1.15 by A2Binder-HL, and 1.33 +/- 0.58 by AbAffinity. In VEGFR, AbPACER recovered 2.33 +/- 0.58 of three panel clones, the highest observed learned-method mean, whereas total count recovered 3/3. No learned method was uniformly best at broader hypothetical budgets. On the public AlphaSeq common split of 11,670 fixed-test variants, AbPACER-MSE recovered 187.0 +/- 2.6 of the true top-384, closely matching AbAffinity (188.0 +/- 2.6) and exceeding A2Binder (175.7 +/- 6.4) and Ens-Grad CNN (154.0 +/- 6.1). AbPACER-MSE updated 1.378 million task-specific parameters, compared with 651.04 million for AbAffinity, and achieved Pearson 0.687 +/- 0.003 and Spearman 0.652 +/- 0.002. Conclusions: AbPACER provides a campaign-specific, parent-aware framework for fixed-budget prioritization from affinity-label-blind phage-display NGS data. At the 384-candidate endpoint, it showed the highest mean recovery among learned methods in both retrospective campaigns. AbPACER-MSE closely matched AbAffinity in true top-384 recovery while updating substantially fewer task-specific parameters. These results motivate prospective evaluation of sequence-conditioned reranking as a complement to count-based prioritization.

bioinformatics↗

Enhanced production of natural shiga toxin by overexpressing A subunit of Stx2e in Stx2e-producing Escherichia coli isolated in South Korea

This study explored the optimal culture conditions for maximizing shiga toxin production in Stx2e-producing Escherichia coli (STEC) 150229, isolated from porcine edema disease (ED), with the goal of preparing a Stx2e toxoid vaccine candidate. High cytotoxicity was observed for this strain [tissue culture cytotoxic dose 50% (104 TCCD50/100 {micro}l)] from 48 h after incubation. Stx2e was overexpressed by transforming pStx2e A into STEC 150229, resulting in the production of recombinant Stx2e A/B complex combined with intrinsic Stx2e B. The enhanced production of Stx2e was evaluated based on the level of cytotoxicity against Vero cells. The highest cytotoxicity (105 TCCD50/100 {micro}l) was observed with the samples of recombinant Stx2e A/B complex eluted with 500 mM imidazole at 48 h of incubation. In conclusion, the recombinant Stx2e A protein forms an active protein complex with the intrinsic Stx2e B component from STEC 150229, producing high levels of shiga toxin.

microbiology↗

E prostanoid receptor 4 expressing macrophages promote the regeneration of the intestinal epithelial barrier upon inflammation

Dysfunctional resolution of intestinal inflammation and altered mucosal healing are essential features in the pathogenesis of inflammatory bowel disease (IBD). Intestinal macrophages are vital in the process of resolution of inflammation but the mechanisms underlying their mucosal healing capacity remains elusive. Here, we describe a subset of E prostanoid receptor 4 (EP4) expressing intestinal macrophages with mucosal healing properties both in human and mice. Notably, Csf1r-iCre EP4-fl/fl mice showed defective mucosal healing and intestinal epithelial barrier regeneration in a dextran sodium sulfate-induced colitis model. Mechanistically, an increased mucosal level of prostaglandin E2 (PGE2) triggers the secretion of chemokine (C-X-C motif) ligand 1 (CXCL1) in monocyte-derived EP4+ macrophages via MAPKs. Subsequently, CXCL1 drives epithelial cell differentiation and proliferation from regenerating crypts during the resolution phase of colitis. Thus, EP4+ intestinal macrophages are essential for the support of the intestinal stem cell niche and for the regeneration of the injured epithelium. One Sentence SummaryProstaglandin E2 licenses E-type prostanoid receptor 4 intestinal macrophage regenerative capacity promoting mucosal healing via the secretion of CXCL1

immunology↗

A meta-analysis of two high-risk prospective cohort studies reveals autism-specific transcriptional changes to chromatin, autoimmune, and environmental response genes in umbilical cord blood

BackgroundAutism spectrum disorder (ASD) is a neurodevelopmental disorder that affects more than 1% of children in the United States. ASD risk is thought to arise from a combination of genetic and environmental factors, with the perinatal period as a critical window. Understanding early transcriptional changes in ASD would assist in clarifying disease pathogenesis and identifying biomarkers and treatments. However, little is known about umbilical cord blood gene expression profiles in babies later diagnosed with ASD compared to non-typically developing (Non-TD) or neurotypical children.\n\nMethodsGenome-wide transcript levels were measured by Affymetrix Human Gene 2.0 array in RNA from umbilical cord blood samples from both the Markers of Autism Risk in Babies--Learning Early Signs (MARBLES) and the Early Autism Risk Longitudinal Investigation (EARLI) high-risk pregnancy cohorts that enroll younger siblings of a child previously diagnosed with ASD. An algorithm-based diagnosis from 36 month assessments categorized the younger sibling as either ASD, typically developing (TD), or not ASD but non-typically developing (Non-TD). 59 ASD, 92 Non-TD, and 120 TD subjects were included and differences were identified in ASD versus TD subjects, with Non-TD versus TD as a specificity control. Meta-analysis was used to combine the results from both studies. Functional enrichments of differentially-expressed genes were examined across diagnostic groups.\n\nResultsWhile cord blood gene expression differences comparing either ASD or Non-TD to TD did not reach genome-wide significance when adjusting for multiple comparisons, 172 genes were nominally differentially-expressed between ASD and TD cord blood (log2(fold change) > 0.1, p < 0.01). These genes were significantly enriched for toxic substance response and xenobiotic metabolism functions, and gene sets involved in chromatin regulation and systemic lupus erythematosus were significantly upregulated (FDR q < 0.05). In contrast, 66 genes were differentially-expressed between Non-TD and TD cord blood, including only 8 genes that were also differentially-expressed in ASD.\n\nConclusionsThis is the first study to identify perinatal gene expression differences in umbilical cord blood specific to ASD. The results of this meta-analysis across two prospective ASD cohorts support involvement of environmental, immune, and epigenetic mechanisms in ASD etiology.

genomics↗